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A B ST R A C T
The present work was designed to exam ine the effect o f  isoteoline on neuronal excitability in mice. Isoteoline 
has previously been shown to behave as a S-HT2 antagonist in a num ber o f experim ental settings with results 
indicating possible selectivity o f the compound for 5-HT2C receptors. These serotonergic receptors are im pli­
cated, amongst many other functions, in modulating seizure susceptibility. M utant mice lacking 5-HT2C re­
ceptors have been shown to suffer spontaneous seizures and higher m ortality. This has lead to the notion that 
serotonin may be involved in the pathogenesis o f epilepsy. However, no 5-HT2 antagonist has so far been 
shown to possess pro-convulsive activity. W e used the model o f  pentylnetetrazole (PTZ)-induced seizures to 
assess the anticonvulsive effect o f  the 5-HT2C agonist chlorophenylpiperazine (mCPP). It proved to prevent 
significantly the clonic and tonic seizures induced by a sub-m axim al dose o f PTZ. 1ST which was expected if 
anything to act pro-convulsively was tested against PTZ at a dose equal to its ED50. No such effect was ob­
served; on the contrary, a slight insignificant anticonvulsive tendency was noted. On the other hand, 1ST 
tended to antagonize the anticonvulsive effect o f  mCPP, but the effect failed to reach statistical significance. 
The results are discussed in the light o f  sim ilar data from the literature concerning 5-HT2C antagonists. In ad­
dition, the failure o f 1ST to significantly antagonize the protective effect o f  mCPP is sought to be explained, 
possibly by its dopam inom im etic activity.
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IN T R O D U C T IO N
Serotonin (5-hydroxytiyptamine, 5-HT) is a mono- 
aminergic neurotransmitter that is known to modulate nu­
merous sensory, motor and behavioural processes in the 
central nervous system. The activation o f  a  large family o f  
receptor subtypes mediates the diverse responses o f  this 
neurotransmitter. Serotonergic mechanisms are implicated 
in the patho-biochemistry o f  a  number o f  neuropsychiatrie 
disorders such as depression, anxiety, eating disorders, etc. 
as well as in the mode o f  action o f  many clinically used 
drugs. Amongst the functions modulated by serotonin is the 
neuronal excitability. Early works point to evidence that the 
5-HT protects from seizures induced by different chemo- 
and electroconvulsive treatments. Literature data show that 
depletion o f  endogenous serotonin lowered the threshold 
for induction o f  seizures and increased severity and inci­
dence o f  seizures (15). O n the other hand, pharmacological 
manipulations enhancing the serotonin function in the brain
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decreased the intensity o f  experimental seizures o f  different 
mechanism and genesis (20). The nature o f  the receptors in­
volved in this inhibiting effect o f  serotonin on the excitabil­
ity o f  the brain is gradually getting revealed during the last 
decade. Experiments with relatively selective ligands indi­
cated the role o f  5-HT2 receptors. M ore recent studies with 
mutant mice specify that animals lacking 5-HT2C receptor 
subtype are extremely susceptible to seizures o f  different 
nature. This lead has opened discussions about the role o f  
similar spontaneous mutations in epileptogenesis (13). 
Isoteoline (1ST) is a  compound derived from glaucine. 
Pharmacological studies have shown it to possess 
antihypertensive effects, on the one side (3), and anxiolytic 
activity, on the other (2,23). The latter has been demon­
strated to depend on blockade o f  5-HT2C receptors. In ad­
dition, 1ST has behaved as a  5-HT2C receptor antagonist in 
a  number o f  other experimental settings known to involve 
this subtype o f  receptors (22,24,25).
In line with the above data, it was pertinent for us to ask the 
question if  1ST could lower the threshold o f  neuronal excit­
ability. This is why the aim o f  the present w ork was to ex­
amine 1ST for possible pro-convulsive action. W e used the 
model o f  pentylenetetrazole-induced seizures in mice and 
investigated the modulating potential o f  the 5-HT2C recep­




as an antagonist. In addition to being used alone, 1ST was 
also tested as a  pre-treatment against mCPP.
M A T E R IA L  A N D  M E T H O D S
Animals
Male albino mice o f  30-40g weight were used. Animals 
were kept under standard conditions in the animal facility 
with a 12:12h light-dark period provided and had their 
usual access to food and water.
R E SU L T S A N D  D ISC U SSIO N
Throughout the experiments, there have been observed no 
statistical differences in latencies to the clonic and tonic 
phases o f  the seizures between treated and control groups 
(not shown). For this reason, only the results from the fre­
quency o f  clonic and tonic seizures are considered below. 
Experiment 1. The effect o f  mCPP was tested at the back­
ground o f  the sub-maximal dose Ы PTZ, 85mg/kg. With 
pre-treatment time o f  20min mCPP at doses 5 and
Table I. Effect o f  mCPP (30 minutes pre-treatm ent time) on the frequency o f  clonic and  tonic seizures induced by 





Clonic seizures Tonic seizures
Frequency % P Frequency % P
Vehicle 
[2 ml/kg]
PTZ 85 10/10 100 10/10 100
mCPP 2.5 PTZ 85 9/10 90 NS 9/10 90 NS
Pentylenetetrazole (PTZ)-induced seizures in mice 
PTZ is a  commonly used chemoconvulsant to generate a 
model o f  clonic-tonic seizures. To define the doses o f  PTZ 
used in the present study, we constructed a  dose-response 
curve in the range o f  10-90mg/kg injected subcutaneously 
(s.c.). E D » was determined graphically to equal approxi­
mately 65mg/kg. In experiment 1, where mCPP was ap­
plied as a  pre-treatment PTZ was injected at a  sub-maximal 
dose o f  85mg/kg, since anticonvulsive effect o f  mCPP was 
expected. mCPP was injected intraperitoneally (i.p.) at two 
intervals - 20 and 30min prior to PTZ. In experiment 2, 
where pro-convulsive effect with 1ST pre-treatment was 
eventually proposed we used the ED50 o f  PTZ. 1ST was 
also given i.p., 30 mm prior to PTZ. In experiment 3, mCPP 
and PTZ were given i.p. and s.c., 30 and 60min, respec­
tively after the i.p. administration o f  1ST. Control mice in 
all experiments received distilled water i.p.
Two types o f  measures were followed: the latency times till 
the onset o f  the clonic and the tonic phase, as well as the fre­
quency o f  the seizures. The clonic phase was defined by a 
myoclonus o f  the forepaws and the rear paws with loss o f 
the writhing reflex for more than 15sec. The tonic phase 
was defined as the tetanic contraction o f  the fore- and rear 
paws followed as a rule by a lethal ex it 
Drugs
Isoteoline hydrobromide has been synthesized in the De­
partment o f  Pharmacology o f  the Higher Medical Institute 
o f  Varna (1). It was used at a dose o f  4mg/kg, which has 
been effective as anxiolytic one both in mice and in rats 
(2,23). Pentylenetetrazole was used in the form o f the com­
mercial preparation under the trade name o f  Corazol 
(Pharmachim).
Statistics
The results were analyzed by chi square test with a level o f 
significance p=0,05. GraphPad Prism software was used.
7,5mg/kg did not alter significantly the fiequency o f  the sei­
zures, either clonic or tonic (not shown). With the 30min 
pre-treatment interval at doses o f  2,5 and 5mg/kg mCPP 
produced a dose-dependent reduction in the number o f  
mice displaying clonic and tonic seizures. The effect was 
statistically significant at the dose 5 mg/kg (p<0,05 and 
p<0,001, respectively) (Table 1).
Experiment 2. The effect o f  1ST was tested against PTZ at 
the E D w of 65mg/kg. In this setting 1ST at the doses used o f 
1 and 4m g/kg caused a slight and dose-independent in­
crease in the number o f  the non-convulsive mice (Table 2).
Table 2. E ffect o f  1ST on the frequency o f  clonic and  
tonic seizures induced by PTZ at the dose o f  EDsn N S - 







Vehicle [2 ml/kg] PTZ 65 6/10 60
1ST 1 PTZ 65 3/10 30 NS
Vehicle [2 ml/kg] PTZ 65 5/10 50
1ST 4 PTZ 65 3/10 30 NS
Experiment 3. A t the dose o f  4mg/kg 1ST reversed the 
anticonvulsive effect o f  mCPP against sub-maximal PTZ 
dose increasing the number o f  the convulsive mice. The ef­
fect, though insignificant, was observed both with clonic 
and tonic seizures (Table 3).
Considerable evidence exists in the literature demonstrating 
the role o f  serotonin in reducing neuronal excitability. Con­
sistent with this, our results with the serotonergic agonist 
m CPP acting to antagonize the convulsive action o f  PTZ in 
mice was not unexpected. It was shown to reduce the inci­
dence both o f  clonic and tonic seizures induced by
34
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Effect o f  isoteoline on seizure susceptibility in pentylenetetrazole-treated mice
s u b -m a x im a l doses o f  PTZ. Although mCPP binds to sev­
eral serotonrgic receptors, it displays a relative preference to 
the 5-HT2C subtype and is often used for functional studies 
o f these receptors (9). Another work with the same agonist 
has demonstrated similar anticonvulsive results, though the 
effect has been shown to depend on the nature o f  the model 
(electroshock vs. PTZ-induced seizures) as well as on the 
animal species (mouse vs. rat) (18). W e chose mCPP be­
cause o f  the evidence that amongst the numerous 
serotonergic receptors in the brain 5-HT2C is the one most 
probably involved in the protective effect o f  serotonin 
agents against increased seizure susceptibility. Recent in­
vestigations with 5-HT2C knock-out mice show that dele­
tion o f  this gene results in a  syndrome characterized by 
spontaneous seizures, lowered seizure threshold, enhanced 
seizure propagation, sound-induced seizure susceptibility 
and increase mortality (4,5,8,16,17). These findings have 
lead to the idea that mutation in 5-HT2C receptors might be 
implicated in epileptogenesis (19).
count for lowered seizure susceptibility (18). Obviously, 
other mechanisms operate in knock-out animals, when this 
protective function is completely absent.
Our results showed further the inability o f  1ST to com­
pletely reverse the anticonvulsive effect o f  mCPP. This ef­
fect was slight and insignificant. In many other experiments 
the antagonism o f 1ST vs. mCPP-mediated effects was 
readily demonstrated (2,22,24,25). The present results, 
however, are intriguing in one another aspect and this is the 
tendency o f  1ST to act in an anticonvuisive manner by itself. 
Though insignificant, this effect seems worth noting for 
two reasons. First, it means that no fear o f  increased 
neuronal excitement should exist in terms o f  the putative 
clinical use o f  1ST as an anti-anxiety agent Second, this 
tendency to display synergistic effect with m CPP may ex­
plain why 1ST failed to antagonize its effect Indeed, it is 
difficult to speculate about the mechanism o f  this effect. In 
there was this respect it is interesting that a  protective effect 
o f  apomorphine against PTZ-induced seizures and found it






Clonic seizures Tonic seizures
Frequency % P Frequency % P
Vehicle 
[2m l/kg]
MCPP 0 + PTZ 85 10/10 100 10/10 100
Vehicle 
[2m l/kg]
MCPP 5 + PTZ 85 5/10 50 <0.05 2/10 20 <0.001
1ST 4 MCPP 5 + PTZ 85 7/10 70 NS 5/5 50 NS
Having in mind the functional pharmacological data that 
has been accumulated about 1ST as an anti-anxiety agent 
acting through inhibition o f  5-HT2C receptors (2,23), it was 
worth testing this compound for ability to provoke in­
creased seizure susceptibility. W e treated mice with 1ST at 
a dose o f  4mg/kg known from our previous works to be 
anxyolitic in this animal species (2). For PTZ we chose a 
dose inducing convulsions in 50%  o f  the treated mice, in 
order to be able to observe eventually a pro-convulsive ef­
fect with 1ST pre-treatment. The results proved to be nega­
tive, i.e., we found no increase in the number o f  convulsing 
mice, neither with clonic, nor with tonic seizures. Our re­
sults were similar to those o f  other analogous studies. The 
apprehension that selective 5-HT2C antagonist may behave 
pro-convulsively has made it necessary for such products to 
be checked accordingly. Recently developed selective an­
tagonists have been tested in screening seizure models. In 
spite o f  the expectations based on data with mutant animals, 
no one o f  these studies found pro-convulsive effects for 
5-HT2C receptor antagonists (10,18,19). It was concluded 
that, in normal adult animals, this receptor subtype may 
usually be subjected to only a  low level o f 
5-hydroxytryptamine tone and its inhibition can not ac-
to be mediated through activation o f  both D1 and D2 recep­
tors (14). There is functional evidence o f  1ST stimulating 
dopamine receptors (21). In this way, the 
anti-PTZ-convulsive tendency o f  1ST might be due to its 
dopaminomimetic activity, and the same mechanism could 
oppose functionally the antagonism o f  1ST vs. mCPP. In 
other words, if  we assume that 1ST displays at the same 
time serotonin antagonist and dopamine agonist-like ac­
tions, these may interact and mutually antagonize each 
other leading to reduced anticonvuisive effect (as a  dopa­
mine agonist) and ability to inhibit the effects o f  mCPP (as 
serotonin antagonist). This presumption is, however, uncer­
tain, since Lazarova and Roussinov have found, though 
considerably earlier, that the dopaminergic and 
serotoniergic systems have an antagonist effect on the con­
vulsive reactivity in the case o f  PTZ convulsion model (II) .  
In conclusion, the present study has provided evidence that 
the 5-HT2C receptor antagonist 1ST lacks pro-convulsive 
activity in the PTZ model. This is important in view o f  its 
anxiolytic activity. The week anticonvuisive effect o f  1ST 
observed and its inability to fully antagonize the effect o f 
the 5-HT2C receptor agonist mCPP may reflect interfer­
ence o f  central dopamine receptors stimulation.
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